Allogeneic human chondrocyte cell therapy is anticipated to be a good alternative to autologous chondrocyte implantation in the near future. Increasing product approvals by regulatory authorities is expected to fuel the market growth over the forecast period. For instance, in July 2017, Kolon TissueGene, Inc. received the South Korea Ministry of Food & Drug Safety (MFDS) for Invossa-K Inj. The product is currently available in the South Korean market and is marketed by Mundipharma and Kolon Pharmaceuticals.

Market Dynamics

Most of the pharmaceutical manufacturers operating in the Europe allogeneic human chondrocyte market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and agreements to strengthen their market presence and expand its geographical footprint. In June, Kolon TissueGene, Inc., a manufacturer and developer of advanced cell and gene therapies, announced the extension of license agreement with Kolon Life Science, Inc., for the sales of Invossa-K Inj, a cell and gene therapy for knee osteoarthritis. The agreement is expected to expand the geographical footprint of Kolon Life Science, Inc. in the Middle East region with the grant of license for Saudi Arabia and United Arab Emirates (UAE) by the year 2024.

Key features of the study:

• This report provides in-depth analysis of the Europe allogeneic human chondrocyte market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Europe allogeneic human chondrocyte market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Kolon TissueGene, Inc. and ISTO Technologies Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, type up-gradation, market expansion, and marketing tactics
• The Europe allogeneic human chondrocyte market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe allogeneic human chondrocyte market

Detailed Segmentation:

• Europe Allogeneic Human Chondrocyte Market, By Application:
  • Osteoarthritis
  • Musculoskeletal System Disorders
  • Others
• Europe Allogeneic Human Chondrocyte Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
• Europe Allogeneic Human Chondrocyte Market, By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Company Profiles
  • Kolon TissueGene, Inc.*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
• ISTO Technologies Inc.

“*” marked represents similar segmentation in other categories in the respective section.